Literature DB >> 17703519

The changing face of meningococcal disease in West Africa.

B Greenwood.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17703519      PMCID： PMC2870640          DOI： 10.1017/s0950268807008825

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN： 0950-2688            Impact factor:   2.451


× No keyword cloud information.
  9 in total

1.  Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso.

Authors:  Josef Decosas; Jean-Baptiste T Koama
Journal:  Lancet Infect Dis       Date:  2002-12       Impact factor: 25.071

2.  Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger.

Authors:  Pascal Boisier; Pierre Nicolas; Saacou Djibo; Muhamed-Kheir Taha; Isabelle Jeanne; Halima Boubacar Maïnassara; Bernard Tenebray; Kiari Kaka Kairo; Dario Giorgini; Suzanne Chanteau
Journal:  Clin Infect Dis       Date:  2007-01-25       Impact factor: 9.079

3.  Emergence of meningococcal meningitis caused by W 135 subgroup in Africa.

Authors:  F Denis; J L Rey; A Amadou; P Saliou; M Prince-David; S M'Boup; M Cadox; I D Mar; J Etienne
Journal:  Lancet       Date:  1982-12-11       Impact factor: 79.321

4.  Epidemic group C meningococcal meningitis in Upper Volta, 1979.

Authors:  C V Broome; M A Rugh; A A Yada; L Giat; H Giat; J M Zeltner; W R Sanborn; D W Fraser
Journal:  Bull World Health Organ       Date:  1983       Impact factor: 9.408

5.  Manson Lecture. Meningococcal meningitis in Africa.

Authors:  B Greenwood
Journal:  Trans R Soc Trop Med Hyg       Date:  1999 Jul-Aug       Impact factor: 2.184

6.  Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana.

Authors:  Sébastien P Gagneux; Abraham Hodgson; Tom A Smith; Thierry Wirth; Ingrid Ehrhard; Giovanna Morelli; Blaise Genton; Fred N Binka; Mark Achtman; Gerd Pluschke
Journal:  J Infect Dis       Date:  2002-02-14       Impact factor: 5.226

7.  Meningitis caused by a serogroup W135 clone of the ET-37 complex of Neisseria meningitidis in West Africa.

Authors:  A Kwara; R A Adegbola; P T Corrah; M Weber; M Achtman; G Morelli; D A Caugant; B M Greenwood
Journal:  Trop Med Int Health       Date:  1998-09       Impact factor: 2.622

8.  Outbreaks of serogroup X meningococcal meningitis in Niger 1995-2000.

Authors:  S Djibo; P Nicolas; J-M Alonso; A Djibo; D Couret; J-Y Riou; J-P Chippaux
Journal:  Trop Med Int Health       Date:  2003-12       Impact factor: 2.622

9.  Serogroup W-135 meningococcal disease during the Hajj, 2000.

Authors:  Jairam R Lingappa; Abdullah M Al-Rabeah; Rana Hajjeh; Tajammal Mustafa; Adel Fatani; Tami Al-Bassam; Amira Badukhan; Abdulhafiz Turkistani; Sahar Makki; Nassen Al-Hamdan; Mohamed Al-Jeffri; Yaqoub Al Mazrou; Bradley A Perkins; Tonja Popovic; Leonard W Mayer; Nancy E Rosenstein
Journal:  Emerg Infect Dis       Date:  2003-06       Impact factor: 6.883
  9 in total
  5 in total

1.  Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.

Authors:  Francesca Micoli; Maria Rosaria Romano; Marta Tontini; Emilia Cappelletti; Massimiliano Gavini; Daniela Proietti; Simona Rondini; Erwin Swennen; Laura Santini; Sara Filippini; Cristiana Balocchi; Roberto Adamo; Gerd Pluschke; Gunnstein Norheim; Andrew Pollard; Allan Saul; Rino Rappuoli; Calman A MacLennan; Francesco Berti; Paolo Costantino
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-04       Impact factor: 11.205

Review 2.  Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.

Authors:  Caroline L Trotter; Martin C J Maiden
Journal:  Expert Rev Vaccines       Date:  2009-07       Impact factor: 5.217

3.  Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa.

Authors:  Rolando Pajon; Andrew M Fergus; Dan M Granoff
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

4.  The Diversity of Meningococcal Carriage Across the African Meningitis Belt and the Impact of Vaccination With a Group A Meningococcal Conjugate Vaccine.

Authors: 
Journal:  J Infect Dis       Date:  2015-04-09       Impact factor: 5.226

5.  Distribution of Bexsero® Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: Implications for immunisation.

Authors:  Carina Brehony; Charlene M C Rodrigues; Ray Borrow; Andrew Smith; Robert Cunney; E Richard Moxon; Martin C J Maiden
Journal:  Vaccine       Date:  2016-08-09       Impact factor: 3.641
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.